Paras Healthcare
- Issue price
- ₹ 693
- Issue size
- ₹ 1,450 Cr.
- Min. investment
- ₹ 14,553
- Listing price
- ₹ 720
- Subscribed
- 2.23x
- Lot size
- 21 shares
- P/E
- 37.72
- RoNW
- 11.83%
- RoCE
- 4.23%
- Debt / Equity
- 3.21
- PAT margin
- 10.38%
- EBITDA margin
- 23.70%
- RoE
- 11.83%
- EPS
- ₹ 18.37
- NAV
- ₹ 44.06
- Promoter stake
- 63.95%
About
Paras Healthcare Limited is a clinical specialty-led hospital platform that provides tertiary and quaternary healthcare through a network of eight hospitals with an aggregate capacity of 2,211 beds as on 31 March 2026. It operates under the Paras Health brand and is based at Paras Twin Towers, Golf Course Road, Sector 54, Gurugram, Haryana. Its critical care infrastructure includes organ and condition-specific ICUs, with 559 ICU beds as on 31 March 2026, up from 425 beds in FY2024. The hospitals employed 1,011 doctors and 1,665 nurses on the same date. The hospitals are spread over five states and one union territory. They are in Gurugram and Panchkula in Haryana, Patna and Darbhanga in Bihar, Kanpur in Uttar Pradesh, Udaipur in Rajasthan, Ranchi in Jharkhand and Srinagar in Jammu and Kashmir. The Gurugram hospital has run for 20 years and the Patna hospital for 12 years, while the newest units at Srinagar and Kanpur have run for three years and two years. Of the eight, four are super-specialty tertiary care hospitals and four are multi-specialty tertiary care hospitals. Six of the eight run on leased premises, five through revenue share arrangements and long-term leases and one under a public private partnership. The business is reported as a single healthcare services segment in a single geography. Work is concentrated in what the company calls CONGOR specialties, meaning cardiac sciences, oncology, neuro sciences, gastro sciences, orthopedics and sports injury, and renal sciences. Together these gave 74.70% of FY2026 revenue from operations, led by oncology at 21.63%, neuro sciences at 13.03% and cardiac sciences at 12.78%. Hospitals outside Gurugram, which the company counts as tier 2 cities, gave 68.18% of FY2026 revenue against 62.35% in FY2024. Operating metrics improved in FY2026. Operational beds rose to 1,502 from 1,465, the bed occupancy rate rose to 61.75% from 50.78%, and occupied bed days rose to 3,38,321 from 2,68,927. In-patient volumes were 1,15,496 and out-patient volumes 7,78,707 in FY2026, against 81,047 and 5,69,139 in FY2024, and the hospitals performed 39,687 surgeries. Average revenue per occupied bed was Rs 47,397.82 per day in FY2026, with the Gurugram hospital at Rs 70,925.76 per day and the Darbhanga hospital at Rs 19,980.75 per day. Average length of stay was 2.93 days. Payments come from three sources. Government schemes and public sector undertakings accounted for 41.28% of FY2026 revenue, self pay patients 33.88% and insurance and third party administrators 24.84%. In FY2024 the same shares were 29.76%, 40.63% and 29.61%. The promoter is Dr. Dharminder Kumar Nagar, the Managing Director, who has been with the company since 2003 and has over 22 years of experience in healthcare. He holds an MBBS from the University of Mysore and a master of philosophy in hospital and health systems management from BITS Pilani.
Timeline
- doneOpens21 Oct
- doneCloses23 Oct
- doneAllotment26 Oct
- doneRefunds27 Oct
- doneDemat credit27 Oct
- doneListing28 Oct
Grey market premium (GMP)
GMP is an unofficial premium from the unregulated grey market. It is not published, verified or regulated by SEBI, NSE or BSE, grey market deals are not legally enforceable, and it is not a reliable indicator of the listing price. Do not apply for an IPO on the basis of GMP. It is not a recommendation of Minerva Capital Research Solutions.
- Highest
- ₹ 96 on 17 Oct 2026
- Lowest
- ₹ 9 on 25 Oct 2026
- First quoted
- ₹ 83 on 14 Oct 2026
Subscription
How many times each investor group bid for its share, as of 28 Oct 2026, 06:30 PM IST.
How much to apply for
The smallest and largest bids for each kind of investor at the upper price band.
| Retail (Min) | 1 | 21 | ₹ 14,553 |
| Retail (Max) | 13 | 273 | ₹ 1,89,189 |
| S-HNI (Min) | 14 | 294 | ₹ 2,03,742 |
| B-HNI (Min) | 69 | 1,449 | ₹ 10,04,157 |
Company overview
Financials
| Revenue from Operations | — | 1,605.95 | 1,294.06 | 1,129.04 |
| Assets | 2,202.88 | 2,071.14 | 1,810.45 | 1,477.66 |
| Total Income | 478.75 | 1,628.78 | 1,314.21 | 1,151.02 |
| Profit After Tax | 49.68 | 43.83 | −57.98 | −15.33 |
| EBITDA | 113.48 | 335.58 | 156.46 | 154.41 |
| NET Worth | 444.96 | 394.94 | 280.49 | 338.51 |
| Reserves and Surplus | 434.86 | 384.84 | 270.73 | 328.75 |
| Total Borrowing | 1,429.49 | 1,393.86 | 1,232.12 | 923.92 |
Strengths
- Revenue from operations grew 24.10% to Rs 1,605.95 crore in FY2026, after 14.62% growth in FY2025.
- The company turned profitable in FY2026 with a profit of Rs 43.83 crore, against a loss of Rs 57.98 crore in FY2025 and a loss of Rs 15.33 crore in FY2024.
- EBITDA grew 114.48% from Rs 156.46 crore in FY2025 to Rs 335.58 crore in FY2026.
- The bed occupancy rate rose to 61.75% in FY2026 from 50.78% in FY2025, with Gurugram at 83.85% and Patna at 73.16%.
- For the quarter ended 30 June 2026 the source lists return on equity of 11.83% and return on capital employed of 4.23%. These are on one quarter's profit and are not annualised.
- Volumes are growing across the network. In-patient volumes rose to 1,15,496 in FY2026 from 81,047 in FY2024 and out-patient volumes to 7,78,707 from 5,69,139, with 39,687 surgeries in FY2026.
- ICU capacity grew to 559 beds as on 31 March 2026 from 425 beds in FY2024, supporting the high-acuity work that gives 74.70% of revenue.
- Cash flow from operations was Rs 163.51 crore in FY2026 against Rs 86.19 crore in FY2025, so the operating profit is converting into cash.
Risks
- The profit record is short. The company lost Rs 57.98 crore in FY2025 and Rs 15.33 crore in FY2024, and FY2026 is its first profitable year of the three shown, with a profit margin of only 2.69% of total income.
- Two subsidiaries, Paras Healthcare (Ranchi) and Plus Medicare Hospitals, together lost Rs 52.09 crore in FY2026, Rs 82.24 crore in FY2025 and Rs 87.27 crore in FY2024.
- Total borrowings rose to Rs 1,393.86 crore as on 31 March 2026 from Rs 923.92 crore in FY2024 against a net worth of Rs 394.94 crore, and the debt to equity ratio was 3.53 times.
- Attrition among doctors, nurses and support staff was 60.38% in FY2026, 66.74% in FY2025 and 65.27% in FY2024.
- Five of the eight hospitals are in North India and gave 66.07% of FY2026 revenue from operations, so one region drives most of the business.
- CONGOR specialties gave 74.70% of FY2026 revenue from operations, so demand for six clinical lines decides the top line.
- Government schemes and public sector undertakings now pay for 41.28% of revenue against 29.76% in FY2024, while self pay fell to 33.88% from 40.63%, and the company says its scheme empanelments have faced suspension and temporary restrictions in the past.
- Six of the eight hospitals run on leased premises, five under revenue share and long-term lease arrangements and one under a public private partnership, so renewal terms are outside the company's control.
- The offer for sale is Rs 950.00 crore of the Rs 1,450.00 crore offer, and only Rs 500.00 crore is fresh money for the company. The promoter is selling Rs 300.00 crore of shares and Commelina Ltd is selling Rs 650.00 crore, as per the estimated amounts shown at the source.
- Average revenue per occupied bed slipped to Rs 47,397.82 per day in FY2026 from Rs 48,088.57 in FY2025, with Srinagar falling to Rs 36,532.56 from Rs 62,401.30, so occupancy rather than pricing drove the growth.
What the money is for
| Prepayment or scheduled repayment, in full or part, of certain outstanding borrowings of the company | 320.9 |
| Investment in wholly owned subsidiary Plus Medicare Hospitals Private Limited, which runs the Srinagar hospital, for repayment or prepayment of its borrowings | 54.1 |
| General corporate purposes | — |
Promoters
- Dr. Dharminder Kumar Nagar
Anchor investors
39 anchors put in ₹ 652.5 Cr., including 24 mutual funds.
| SBI MULTI ASSET ALLOCATION FUND | 9,37,923 | 65 | 9.96% |
| SBI INFRASTRUCTURE FUND | 7,21,497 | 50 | 7.66% |
| SBI HEALTHCARE OPPORTUNITIES FUND | 5,05,050 | 35 | 5.36% |
| SBI BALANCED HYBRID FUND | 4,32,894 | 30 | 4.6% |
| SBI DIVIDEND YIELD FUND | 2,88,603 | 20 | 3.07% |
| HDFC MULTI-ASSET FUND | 75,033 | 5.2 | 0.8% |
| HDFC BUSINESS CYCLE FUND | 75,033 | 5.2 | 0.8% |
| HDFC SMALL CAP FUND | 3,80,940 | 26.4 | 4.05% |
| HDFC INFRASTRUCTURE FUND | 46,179 | 3.2 | 0.49% |
| HDFC PHARMA & HEALTHCARE FUND | 2,88,603 | 20 | 3.07% |
| ISIF HYBRID LONG-SHORT FUND | 1,44,291 | 10 | 1.53% |
| ISIF EQUITY LONG-SHORT FUND | 72,156 | 5 | 0.77% |
| ICICI PRUDENTIAL EXPORTS & SERVICES FUND | 2,16,447 | 15 | 2.3% |
| KOTAK CONTRA FUND | 2,16,447 | 15 | 2.3% |
| KOTAK HEALTHCARE FUND | 2,16,447 | 15 | 2.3% |
| ABU DHABI INVESTMENT AUTHORITY-STABLE | 10,10,058 | 70 | 10.73% |
| BLACKROCK GLOBAL FUNDS - INDIA FUND | 3,38,478 | 23.46 | 3.59% |
| BLACKROCK GLOBAL FUNDS-ASIAN DRAGON FUND | 3,46,941 | 24.04 | 3.68% |
| WHITEOAK CAPITAL MID CAP FUND | 2,74,176 | 19 | 2.91% |
| WHITEOAK CAPITAL MULTI CAP FUND | 93,786 | 6.5 | 1% |
| WHITEOAK CAPITAL PHARMA & HEALTHCARE FUND | 1,01,010 | 7 | 1.07% |
| WHITEOAK CAPITAL MULTI ASSET ALLOCATION FUND | 36,078 | 2.5 | 0.38% |
| WHITEOAK CAPITAL EQUITY FUND | 72,156 | 5 | 0.77% |
| WHITEOAK CAPITAL EQUITY FUND-II | 2,16,426 | 15 | 2.3% |
| EASTSPRING INVESTMENTS-UNIT TRUST-DRAGON PEACOCK FUND | 2,88,582 | 20 | 3.06% |
| GOVERNMENT PENSION FUND GLOBAL | 2,16,447 | 15 | 2.3% |
| NATIXIS INTERNATIONAL FUNDS (LUX) I-LOOMIS SAYLES GLOBAL EMERGING MARKETS EQUITY FUND | 2,16,468 | 15 | 2.3% |
| ICICI PRUDENTIAL LIFE INSURANCE CO.LTD. | 5,05,050 | 35 | 5.36% |
| MOTILAL OSWAL CONSUMPTION FUND | 1,44,312 | 10 | 1.53% |
| EDELWEISS EQUITY SAVINGS FUND | 72,156 | 5 | 0.77% |
| EDELWEISS RECENTLY LISTED IPO FUND | 72,156 | 5 | 0.77% |
| 360 ONE PRIVATE EQUITY FUND-SERIES II | 1,44,312 | 10 | 1.53% |
| BARODA BNP PARIBAS HEALTH & WELLNESS FUND | 72,201 | 5 | 0.77% |
| ITI ELSS TAX SAVER FUND | 72,156 | 5 | 0.77% |
| EDELWEISS LIFE INSURANCE CO.LTD. | 72,156 | 5 | 0.77% |
| CANARA HSBC LIFE INSURANCE CO.LTD. | 72,156 | 5 | 0.77% |
| INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD. | 1,44,312 | 10 | 1.53% |
| SUSQUEHANNA PACIFIC PTY.LTD. | 1,44,312 | 10 | 1.53% |
| CITIGROUP GLOBAL MARKETS MAURITIUS PVT.LTD. | 72,156 | 5 | 0.77% |
Registrar, lead managers and documents
- Listing on
- BSE, NSE
- Face value
- ₹ 1 a share
- Registrar
- MUFG Intime India Private Limited
- Lead managers
- JM Financial Ltd., Nuvama Wealth Management Ltd., Bofa Securities India Limited
- Red herring prospectus (RHP)
- Open
- Draft prospectus (DRHP)
- Open
- Basis of allotment
- Open
IPO dates, prices, grey market premium (GMP), subscription and the company overview: IPO Guru, updated three times a day. GMP is an unofficial premium from the unregulated grey market. It is not published, verified or regulated by SEBI, NSE or BSE, grey market deals are not legally enforceable, and it is not a reliable indicator of the listing price. Do not apply for an IPO on the basis of GMP. It is not a recommendation of Minerva Capital Research Solutions.
Our recommendations are research opinions, not investment advice. Read the offer document (RHP) and consult your financial adviser before investing.